NanOlogy Fact Sheet (Jan 2020)

In patients with solid carcinomas, NanOlogy™ has demonstrated that local administration of patented submicron particles continuously exposes primary tumors to therapeutic levels of taxanes for several weeks, causes a sustained tumoricidal response, produces clinical benefits without local or systemic toxicity, and may facilitate treatment of metastatic disease.


Video Highlights of NanoPac® Injection for Pancreatic Cancer

Highlights of the presentation by Dr. Neil Sharma, President, Parkview Cancer Institute; Director of Advanced Interventional Endoscopy and Endoscopic Oncology Programs, Medical Director GI Oncology.  View the full 7-minute video here.